Cobitolimod sodium
Cobitolimod (DIMS0150) sodium is a DNA oligonucleotide agonist of TLR9 agonist that activates the TLR9 signaling pathway. Cobitolimod sodium induces the production of anti-inflammatory cytokines, balances Th17/T-reg cell responses, inhibits IL-17 expression and Th17 responses, induces IL-10 expression/production, regulatory T cells and Tr1 cells, and polarization of macrophages toward the wound-healing M2-like phenotype. Cobitolimod sodium can be used for research on ulcerative colitis.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 1527479-55-5
- Fòrmula: C185H215N73O105P18S6Na18
- Peso molecular:5925.2 (free acid)
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
Descripciòn
IC50 & Target
[1]|
TLR9 |
In Vitro
Cobitolimod (25 µM; 8 days) sodium biases ulcerative colitis specimen-derived CD14+ monocyte-derived macrophages toward an IL10-producing CD163+CD206+ wound-healing phenotype and reduces CD80+ pro-inflammatory macrophages[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c (female, 8 weeks old) injected with DSS[2]
-
Dosage:40 µg; 84 µg; 250 µg
-
Administration:rectal administration; on days 4 and 8; two total administrations during the 10-day DSS protocol
-
Result:Reduced DSS-induced body-weight loss and reduced DAI compared with placebo-treated mice from day 6 through the end of the experiment.
All dose groups showed diminished endoscopic signs of inflammation by MEICS.
Reduced the histopathological score, with greater suppression in the 84 µg and 250 µg groups than in the 40 µg group.
Microarray analysis of LPMCs from DSS mice showed downregulation of pro-inflammatory genes, upregulation of IL10 signalling, and downregulation of IL17 signalling.
Flow cytometry of colonic LPMCs showed reduced RorγT+IL17+, RorγT+, and IL17+ T cells, with no observed differences in Th1 or Th2 cells and their associated transcription factors T-bet and GATA3.
Colonic qRT-PCR showed reduced IL6, IL17F, and IL17A mRNA and increased FoxP3 mRNA; no difference was observed for IL10 mRNA.
Immunofluorescence of day 10 colon showed decreased IL17+ cells and increased IL10+ and FoxP3+ cells.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 1527479-55-5
-
Peso molecular 5925.2 (free acid)
-
Fòrmula C185H215N73O105P18S6Na18
-
SMILES
[Cobitolimod (sodium)]
-
Synonyms
Kappaproct sodium; DIMS0150 sodium
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)